These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cardiotoxicity of cancer chemotherapy: implications for children. Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964 [TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503 [TBL] [Abstract][Full Text] [Related]
26. Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy. Shahid I; Yamani N; Ali A; Kumar P; Figueredo V; Unzek S; Mookadam F Am J Cardiol; 2021 Oct; 156():142-145. PubMed ID: 34362551 [No Abstract] [Full Text] [Related]
27. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review. Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912 [TBL] [Abstract][Full Text] [Related]
29. Cardiac testing to manage cardiovascular risk in cancer patients. Davis M; Witteles RM Semin Oncol; 2013 Apr; 40(2):147-55. PubMed ID: 23540740 [TBL] [Abstract][Full Text] [Related]
30. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Jones RL; Ewer MS Expert Rev Anticancer Ther; 2006 Sep; 6(9):1249-69. PubMed ID: 17020459 [TBL] [Abstract][Full Text] [Related]
31. Optimizing cardio-oncology programs for cancer patients. Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828 [No Abstract] [Full Text] [Related]
32. Cardiac Outcomes With Pregnancy After Cardiotoxic Therapy for Childhood Cancer. Thompson KA; Hildebrandt MA; Ater JL J Am Coll Cardiol; 2017 Feb; 69(5):594-595. PubMed ID: 28153113 [No Abstract] [Full Text] [Related]
33. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. Upshaw JN Curr Oncol Rep; 2020 Jun; 22(7):72. PubMed ID: 32564220 [TBL] [Abstract][Full Text] [Related]
34. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. Li M; Russo M; Pirozzi F; Tocchetti CG; Ghigo A Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118493. PubMed ID: 31233802 [TBL] [Abstract][Full Text] [Related]
35. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150 [TBL] [Abstract][Full Text] [Related]
36. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This? Caron J; Nohria A Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677 [TBL] [Abstract][Full Text] [Related]
37. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. de Geus-Oei LF; Mavinkurve-Groothuis AM; Bellersen L; Gotthardt M; Oyen WJ; Kapusta L; van Laarhoven HW J Nucl Med; 2011 Apr; 52(4):560-71. PubMed ID: 21421717 [TBL] [Abstract][Full Text] [Related]